Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate
about
sameAs
Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevanceA Quest to Identify Prostate Cancer Circulating Biomarkers with a Bench-to-Bedside PotentialGrowth delay of human bladder cancer cells by Prostate Stem Cell Antigen downregulation is associated with activation of immune signaling pathways.Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages.Quantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibodyOxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates.Novel diagnostic biomarkers for prostate cancer.Positive and negative regulation of prostate stem cell antigen expression by Yin Yang 1 in prostate epithelial cell linesDendritic cell-directed vaccination with a lentivector encoding PSCA for prostate cancer in miceEvaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging.Antiproliferative and apoptotic effects of a specific antiprostate stem cell single chain antibody on human prostate cancer cells.Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.The Quantified Level of Circulating Prostate Stem Cell Antigen mRNA relative to GAPDH Level Is a Clinically Significant Indictor for Predicting Biochemical Recurrence in Prostate Cancer Patients after Radical Prostatectomy.Genetic variant as a selection marker for anti-prostate stem cell antigen immunotherapy of bladder cancerPSCA and Oct-4 expression in the benign and malignant lesions of gallbladder: implication for carcinogenesis, progression, and prognosis of gallbladder adenocarcinoma.Prostate stem cell antigen: a prospective therapeutic and diagnostic target.Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumorsDNA vaccination: using the patient's immune system to overcome cancerImmunotherapy for prostate cancer: lessons from responses to tumor-associated antigens.Characterization of reactive stroma in prostate cancer: involvement of growth factors, metalloproteinase matrix, sexual hormones receptors and prostatic stem cells.Expression of prostate stem cell antigen is downregulated during flavonoid-induced cytotoxicity in prostate cancer cells.Exploratory investigation of PSCA-protein expression in primary breast cancer patients reveals a link to HER2/neu overexpression.Tumor-associated antigens for specific immunotherapy of prostate cancerPSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells.PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer.
P2860
Q24646761-0D03F7F1-C584-4686-863B-F0F2A450E86AQ27022638-F6AA4ADC-CC7F-4758-9F67-62585AD41CF3Q33550600-13DF59D0-AED8-4186-93B8-04A8082F68D5Q33606027-89CC4EF8-F073-43D1-8B65-9E3B2821A978Q33738280-F42D67DD-10C9-490F-962C-6D00860CADDDQ34162875-F093C102-1A4B-485F-B1D4-F1E172376594Q34231678-55AF017B-3766-4DD5-9E85-8BF98BA5CE30Q34247379-585CA3D8-76A5-4B3B-8B74-FF43E77B0DE3Q34472125-500A74C1-AFF7-4D08-8506-3C57FF090D86Q35025244-EB21C8E7-4452-450C-9FA3-718890DB5FECQ35082285-1F337C85-B5A8-44FE-81F9-9B79D078D7B0Q35459059-A7753A9B-87FB-4557-A632-0C2C9BD45B9FQ36191947-03DC72A3-ED78-46DE-858C-03E368DC24EDQ36507544-ABAF690C-97AE-4765-BFDC-6FA994CD682DQ37104978-18CA8C97-6BCC-4700-8EB3-5F1541219996Q37186552-6CC3B925-85B6-404B-98D1-DA33F1181589Q37289040-F45D1B8A-52B6-4855-BDDC-2A53A3424D3FQ37825422-5E28EDE9-E6BA-4A44-981A-6F7CFFBF95D3Q38212231-8AA0985D-6E8F-4C47-B591-4C58DB12A2A0Q38532446-BFBD5DA9-D436-44E8-BF3A-E7DA4BA62FC1Q41116482-7DF63294-C13F-40C5-9E4B-B9F1C58D6A94Q41551352-8BB57031-10FC-42D0-BBCB-1F87B352153AQ41977894-2D8A65B8-613B-4DB0-B46D-10AD4DBE6619Q47920923-95C32284-8E29-4063-A419-4D2CA6DB7407Q54989451-0BF78144-5888-40A0-BA50-20A6A31C0432
P2860
Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Prostate stem cell antigen as ...... efficacy of an immunoconjugate
@ast
Prostate stem cell antigen as ...... efficacy of an immunoconjugate
@en
Prostate stem cell antigen as ...... efficacy of an immunoconjugate
@nl
type
label
Prostate stem cell antigen as ...... efficacy of an immunoconjugate
@ast
Prostate stem cell antigen as ...... efficacy of an immunoconjugate
@en
Prostate stem cell antigen as ...... efficacy of an immunoconjugate
@nl
prefLabel
Prostate stem cell antigen as ...... efficacy of an immunoconjugate
@ast
Prostate stem cell antigen as ...... efficacy of an immunoconjugate
@en
Prostate stem cell antigen as ...... efficacy of an immunoconjugate
@nl
P2093
P1433
P1476
Prostate stem cell antigen as ...... efficacy of an immunoconjugate
@en
P2093
Brigitte Devaux
Christine Tan
David Eberhard
Franklin Peale
Gilbert A Keller
Gretchen Frantz
Hartmut Koeppen
Ilona Holcomb
JoAnne Hongo
Kenneth Hillan
P304
P407
P577
2002-05-01T00:00:00Z